{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.7","value":"131"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Etoposide Day 1 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.4","value":"146"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Etoposide Day 3 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.4","value":"50.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Free Carboplatin Day 1 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.3","value":"137"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Total Carboplatin Day 1 Cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"AUC0-inf of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.","dispersionType":"Standard Deviation","groups":[{"description":"The 1st cohort in Part 1 received trilaciclib 200 mg/m\\^2, IV once daily on Days 1 to 3 of each 21-day E/P cycle. The 2nd cohort in the Phase 1b dose-finding portion of Part 1 \\& the Phase 2a expansion cohort in Part 1 received trilaciclib 240 mg/m\\^2, IV once daily on Days 1 to 3 of each 21-day E/P cycle. Participants received standard E/P chemotherapy in 21-day cycles. Carboplatin dose was calculated using the Calvert formula with a target AUC = 5 (maximum 750 mg) IV on Day 1. Etoposide 100 mg/m\\^2 was given IV daily on Days 1, 2, \\& 3 of each 21-day cycle. Trilaciclib was only given with E/P therapy. If E/P therapy was discontinued, trilaciclib was also to be discontinued. The interval between doses of trilaciclib on successive days was not greater than 28 hours \\& between the dose of trilaciclib \\& the first dose of chemotherapy on a given day (etoposide or carboplatin) not greater than 4 hours","id":"OG000","title":"Part 1: Dose Finding/Expansion"}],"paramType":"MEAN","populationDescription":"PK analysis set - included all participants with evaluable PK profiles for both treatments and analytes","reportingStatus":"POSTED","timeFrame":"Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 AUC0-inf values)","title":"AUC0-inf of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1","type":"SECONDARY","unitOfMeasure":"h*μg/mL"}